PCM
IMVT icon

Penserra Capital Management’s Immunovant IMVT Stock Holding History

Penserra Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,597
Closed -$14K – 1079
2022
Q2 		$14K Buy
3,597
+666
+23% +$2.88K ﹤0.01% 1176
2022
Q1 		$16K Sell
2,931
-961
-25% -$5.99K ﹤0.01% 1312
2021
Q4 		$33K Sell
3,892
-2,917
-43% -$24.1K ﹤0.01% 1128
2021
Q3 		$59K Sell
6,809
-4,989
-42% -$45K ﹤0.01% 1001
2021
Q2 		$124K Sell
11,798
-4,728
-29% -$66K ﹤0.01% 744
2021
Q1 		$265K Sell
16,526
-5,578
-25% -$147K ﹤0.01% 545
2020
Q4 		$1.02M Buy
22,104
+19,280
+683% +$891K 0.02% 309
2020
Q3 		$106K Buy
+2,824
New +$84.9K ﹤0.01% 481

Other funds holding IMVT

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Penserra Capital Management's IMVT Position: Q3 2022 in Review

Penserra Capital Management sold out of Immunovant (IMVT) in Q3 2022, closing a stake of 3,597 shares — an estimated $14K sold.

Penserra Capital Management first reported a position in IMVT in Q3 2020 and held it in 8 quarters. The position peaked at $1.02M in Q4 2020. 112 funds tracked by Wall St. Rank hold IMVT as of Q3 2022.

  • Penserra Capital Management reported no remaining Immunovant position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 3,597 Immunovant shares in Q3 2022, an estimated $14K.
  • Penserra Capital Management first reported a position in Immunovant in Q3 2020 and held it in 8 quarters.
  • Penserra Capital Management's Immunovant position peaked at $1.02M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held Immunovant as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.